Manufacturing, Fill/Finish

Aug 01, 2007
BioPharm International
Drug delivery technologies have the potential to enable drug candidates with poor pharmaceutical or biopharmaceutical properties, both for macromolecule and traditional compounds. While there have been many success stories to date, the future offers even more promise. In this article, the author surveys the top ten areas in drug delivery looking forward.
Nov 09, 2006
The many benefits of disposable technologies, such as significant savings in time, labor and capital, as well as ease of scalability and flexibility, have led to the growing trend of adopting disposable technologies in bioprocess manufacturing processes.
Oct 01, 2006
BioPharm International
By BioPharm International Editors
Formulations for pulmonary inhalation comprise spherical, porous particles that are 1–3 microns in diameter.
Jul 01, 2006
BioPharm International
By BioPharm International Editors
Disposables require less space than conventional equipment, and they can be assembled offsite into complete process trains.
Jun 27, 2006
BioPharm International
On August 12, 2003, Johnson & Johnson began recalling certain batches of its anemia drug, Eprex (epoetin alfa, sold as Procrit in the US), in most countries outside of the United States.
Jun 27, 2006
BioPharm International
By BioPharm International Editors
A symposium at the AAPS National Biotechnology Conference in Boston, June 19-22, 2006, addressed key concerns and new developments in manufacturing biologic products in a sterile environment.
Sep 01, 2003
BioPharm International
By BioPharm International Editors
The author shares a case example that applies an eight-step structured approach to the front-end engineering of a vaccine R&D fill-and-finish facility project. Assumptions, issues, action items, owner interface, and interdisciplinary coordination are covered to meet the challenges of timing, technology, compliance, and cost.
native1_300x100
lorem ipsum